Zhimei Du

Company: Merck

Job title: Executive Director & Global Head of Process Cell Sciences

Email: zhimei.du@merck.com

Bio:

Zhimei graduated from Cornell University Medical College – Memorial Sloan Kettering Cancer Center joint Immunology Program, studying molecular mechanisms in tumor immunology and autoimmune disease areas. After graduation, she joined Robert G. Roeder’s laboratory at The Rockefeller University, exploring the genetic/epigenetic regulation mechanisms during lymphocyte development and leukemia genesis. She started her industrial career at Regeneron as protein engineer for bi-specific antibodies. Later, she joined Amgen followed by Teva Pharmaceuticals focusing on bioprocess development of biotherapeutics manufacturing. Zhimei had extensive experience in cell/gene therapy. She led cell/gene therapy clinical programs for type I diabetes at Diabetes Research Institute, U. of Miami. Currently she is the Executive Director at Merck & Co, leading Process Cell Sciences Department, including cell therapy process development, cell line development, cell banking, and in-process characterization. Zhimei is also the leader and core member of multiple Industrial-wide Consortium teams, setting up road map and establishing industrial common practices in various biotherapeutics development areas, including sponsoring BPOD Cell/Gene therapy workstream, ADC/Bispeicifics team at BPOD/NIMBLE, IQ comparability team, IQ sequence variant consortium team, IQ and BPOD Cell/Gene Therapy consortium team.

Location: Kenilworth, New Jersey, United States

LinkedIn: https://www.linkedin.com/in/zhimei-du-23960a9/

For contact information, please email james.milburn@hansonwade.com